Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.

E. Andreopoulou; A. P. Chen; J. Zujewski; M. Kim; D. L. Hershman; K. Kalinsky; T. Cigler; L. T. Vahdat; G. Raptis; B. Ramaswamy; Y. Novik; F. Muggia; J. A. Sparano

doi:10.1200/jco.2011.29.15_suppl.tps114

Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps114 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS114-TPS114

Author(s):

E. Andreopoulou ◽

A. P. Chen ◽

J. Zujewski ◽

M. Kim ◽

D. L. Hershman ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Double Blind Placebo ◽

Metronomic Cyclophosphamide

Download Full-text

OT3-01-17: Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Low-Dose Metronomic Cyclophosphamide Alone or in Combination with Veliparib (ABT-888) in Chemotherapy-Resistant ER and/or PR-Positive, HER2/neu-Negative Metastatic Breast Cancer: New York Cancer Consortium Trial P8853.

10.1158/0008-5472.sabcs11-ot3-01-17 ◽

2011 ◽

Author(s):

E Andreopoulou ◽

AP Chen ◽

JA Zujewski ◽

K Kalinsky ◽

L Vahdat ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Double Blind Placebo ◽

Metronomic Cyclophosphamide

Download Full-text

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

Annals of Oncology ◽

10.1093/annonc/mdn689 ◽

2009 ◽

Vol 20 (4) ◽

pp. 642-647 ◽

Cited By ~ 18

Author(s):

T. Li ◽

P.J. Christos ◽

J.A. Sparano ◽

D.L. Hershman ◽

S. Hoschander ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Farnesyltransferase Inhibitor ◽

Hormone Receptor Positive

Download Full-text

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Breast Cancer Research and Treatment ◽

10.1007/s10549-008-0251-7 ◽

2008 ◽

Vol 117 (1) ◽

pp. 83-89 ◽

Cited By ~ 28

Author(s):

Aruna Mani ◽

Julie Roda ◽

Donn Young ◽

Michael A. Caligiuri ◽

Gini F. Fleming ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Metastatic Breast

Download Full-text

A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.017 ◽

2008 ◽

Vol 8 (2) ◽

pp. 162-167 ◽

Cited By ~ 6

Author(s):

Orlando Silva ◽

Gilberto Lopes ◽

Daniel Morgenzstern ◽

Christopher Lobo ◽

Philomena Doliny ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

npj Breast Cancer ◽

10.1038/npjbcancer.2016.37 ◽

2016 ◽

Vol 2 (1) ◽

Cited By ~ 10

Author(s):

Kerin Adelson ◽

Bhuvaneswari Ramaswamy ◽

Joseph A Sparano ◽

Paul J Christos ◽

John J Wright ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii

Download Full-text

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

10.1158/1538-7445.sabcs16-s1-02 ◽

2017 ◽

Cited By ~ 14

Author(s):

NS Kornblum ◽

J Manola ◽

P Klein ◽

B Ramaswamy ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4

10.1158/0008-5472.sabcs13-ot2-6-07 ◽

2013 ◽

Cited By ~ 1

Author(s):

M Martin ◽

N Batista ◽

M Shtivelband ◽

A Chan ◽

S Delaloge ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3k Pathway ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Pathway Activation

Download Full-text

Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

10.1158/1538-7445.sabcs14-s6-03 ◽

2015 ◽

Cited By ~ 1

Author(s):

Kerin B Adelson ◽

Bhuvaneswari Ramaswamy ◽

Joseph A Sparano ◽

Paul J Christos ◽

John J Wright ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii

Download Full-text

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

The Breast ◽

10.1016/j.breast.2019.02.002 ◽

2019 ◽

Vol 45 ◽

pp. 22-28

Author(s):

A. Mavratzas ◽

S. Baek ◽

B. Gerber ◽

M. Schmidt ◽

V. Moebus ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06216-5 ◽

2021 ◽

Author(s):

Zijing Wang ◽

Jiaxuan Liu ◽

Fei Ma ◽

Jiayu Wang ◽

Yang Luo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy Study ◽

Her2 Positive ◽

Safety And Efficacy ◽

Metronomic Vinorelbine

Download Full-text